On July 29, 2024 Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, reported participation in two investor conferences in August: BTIG virtual Biotechnology Conference, August 5-6, 2024, and Canaccord Genuity (CG) 44th Annual Growth Conference, August 13-14, 2024 in Boston (Press release, Akebia, JUL 29, 2024, View Source/news-releases/news-release-details/akebia-therapeutics-present-upcoming-investor-conferences-1" target="_blank" title="View Source/news-releases/news-release-details/akebia-therapeutics-present-upcoming-investor-conferences-1" rel="nofollow">View Source [SID1234645139]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BTIG Biotechnology Conference
John Butler, Chief Executive Officer, will participate in a fireside chat on Tuesday, August 6, at 8:00 am EST.

CG 44th Annual Growth Conference
Mr. Butler will present on Wednesday, August 14 at 8:30 a.m. EST. A webcast of the presentation can be accessed through the "Investors" section of Akebia’s website at View Source following the conference.